Androgenetic Alopecia Research Articles

STUDY ON KESHA SHAREERA W.S.R TO KHALITYA (MALE PATTERN BALDNESS) IN RELATION WITH DAIHIKA PRAKRUTI.

Ayurveda is one of the oldest scientific medical systems in the world with strong evidence of experiencing good life. However, it is not only the system of medicine in the congenital sense of curing diseases. It is also a way of life that teaches us how to maintain and protect our own health and lead a healthy life, Hence, it is sincerely a holistic and fundamental medical system. According to Acharya Sushruta, the Kesha is one of the Pitruja Bhava. He has mentioned in Nidanasthana that under the heading explained Indralupta, Khalitya, and Ruhya are the same. Pitta along with Vata by involving the roots of hair (Romakoopa) causes the falling of hair and then after Shleshma along with Shonita obstructs the channel of Romakoopa leading to the degeneration of the hairs. Ayurveda is based on the concepts of Prakruti inherited at the time of Shukra Shonita Samyoga, prior to birth defined as Prakruti. As the Prakruti of a person remains stable throughout the life of an individual, it is helpful in predicting a particular disease, the prognosis of that illness, and the selection of therapy. The Kesha and Prakruti are interrelated, people of different Prakruti have different types of Kesha. Here for the assessment of male pattern baldness, the Hamilton Norwood scale is used. In the present Westernized culture, other dietary habits, and different hair care products like chemical-based oils, shampoos, conditioners, soaps, etc, have made hair either get premature or to falling of hair. So, the individual develops an inferiority complex, having a latent impact on one’s psychological behavior. So, our in-tention is to know which Prakruti person will get earlier Khalitya and the same will be studied here.

Photobiostimulation Therapy (PBST) and Pulsed Electromagnetic Field Therapy (PEMF) in Hair Loss Treatment: Multicentric, Retrospective, Case-Control Study.

The combined use of micro-needling (MND), growth factors (GFs), and low-level light/laser therapy (LLLT), here identified as photobiostimulation therapy (PBST) and pulsed electromagnetic field therapy (PEMF), is a hair loss (HL) treatment that needs to be standardized as it seems to have promising effects on hair regrowth (HR-G). The study compared the clinical and instrumental results obtained in patients affected by androgenic alopecia (AGA) and HL related to COVID-19 treated using PEMF combined with PBST with those obtained by only PBST. A multicentric, retrospective, observational, case-control study was conducted. Fifty-three patients were initially enrolled (30 males classified as stages I-III vertex by the Norwood-Hamilton scale, while 23 females classified in stages I-II by the Ludwig scale). Forty patients (20 females and 20 males) were analyzed after exclusion and inclusion criteria assessment. Twenty patients were treated with the combined use of PEMF and PBST (study group - SG) while 20 patients were treated with PBST (control group -CG). The HR-G was evaluated through photography, physician's, and patient's global assessment scales, in addition to standardized phototrichograms, during a short follow-up at T0-baseline, T1-16 weeks. The promising results in SG patients, represented by a hair count (HC) increase of 14 hairs/0.65cm2 at T1 after 16 weeks in the targeted area, compared with the baseline results (41 ± 2 hairs/0.65cm2 at T1 versus 27 ± 2 hairs/0.65cm2 at baseline), were observed using computerized trichograms. There was a statistically significant difference in HR-G (p = 0.0325) compared with an HC increase of 11 ± 2 hairs/0.65cm2 in the CG. The comparison between SG and CG indicated that PEMF combined with PBST was a more efficient strategy in HR-G in terms of HC improvement than PBST alone. This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .

Australian dermatologists' prescribing behaviours for female androgenetic alopecia

AbstractFemale androgenetic alopecia (FAGA) affects approximately half of women during their lifetime and can have significant psychological impact. Despite its prevalence, treatment options have traditionally been limited. In this study, we examined the current prescribing patterns of Australian dermatologists for FAGA (n = 54), including the use of spironolactone, systemic minoxidil, topical minoxidil and combination treatments.

Clinical Features of Patients Treated With Hair Transplants in Female Pattern Hair Loss.

Hair transplantation (HT) has been reported to be effective for the treatment of female-pattern hair loss (FPHL). Few studies have investigated HT in FPHL. To evaluate the clinical features of FPHL treated with HT and analyze the real-world results of HT. We conducted a retrospective chart review of 195 FPHL patients who underwent hair transplants. The patients' demographics, clinical features, and clinical courses of HT were recorded. The mean (±SD) age of patients was 49.1±11.9 years. Analysis of the severity of hair loss showed that 31.8%, 49.7%, and 18.5% of patients had F1, F2, and F3 types of hair loss (according to the BASP Classification); 88.2% of patients had more than 75% satisfaction with HT. The satisfaction level was significantly higher in the group that had the highest number of hairs implanted. Complications such as pain, facial edema, folliculitis, scar, paresthesia, telogen effluvium were found. This study could provide substantial information of HT in FPHL. Clinicians could deliver more sufficient counsel to FPHL patients about HT.

131 Exploring the Scalp Microbiome Landscape: A Cross-Sectional Study of Female Pattern Hair Loss in Indian Women

131 Exploring the Scalp Microbiome Landscape: A Cross-Sectional Study of Female Pattern Hair Loss in Indian Women

508 Hair follicle rejuvenation is induced by topical minoxidil administration in a humanized mouse model of androgenetic alopecia

508 Hair follicle rejuvenation is induced by topical minoxidil administration in a humanized mouse model of androgenetic alopecia

Phytochemicals in hair care: A review of natural ingredients and their applications

Phytochemicals are increasingly being used in hair care products due to their potential benefits for hair growth, strength, and texture. This review article discusses the various natural ingredients used in hair care products, including herbs, essential oils, and plant extracts. The article highlights the benefits of using phytochemicals in hair care, including their ability to promote hair growth, reduce, dandruff, and improve scalp health. The review also discusses the different types of hair loss, including alopecia areata, androgenetic alopecia, and telogen effluvium. Furthermore, the article explores the various applications of phytochemicals in hair care, including their use in hair oils. Overall, this review article provides a comprehensive overview of the use of phytochemicals in hair care and highlights their potential benefits for promoting healthy hair.

Evaluation of Dutasteride-Loaded Liposomes and Transfersomes for Follicular-Targeting for Androgenic Alopecia Topical Treatment

Background/Objectives: Although androgenic alopecia is the most prevalent among non-cicatricial alopecia, it still lacks an effective and safe treatment. Dutasteride (DUT) shows promising results in hair regrowth; however, oral DUT intake causes serious sexual adverse events. Hence, we produced liposomes with different bilayer structures and evaluated the capability of such systems in increasing DUT accumulation in the hair follicles. Methods: In vitro skin penetration tests were performed with porcine ear skin, and the follicular targeting factor (Tf) was calculated as the ratio between DUT amount in HFs and DUT recovered from the sum of all skin layers. Results: While the stiffer DUT-loaded liposome was not able to target the hair follicles in 12 h (Tf = 0.15), a DUT-loaded liposome with an edge activator in its composition, i.e., transfersomes, promoted better control over DUT release and a higher Tf (0.32) (p < 0.005). Conclusions: Transfersomes present higher affinity with DUT providing a better controlled release; hence, they are a better option for DUT follicle targeting compared to liposomes. Further formulation optimizations are needed aiming to prolong such targeting effect.

Isoquercitrin promotes hair growth through induction of autophagy and angiogenesis by targeting AMPK and IGF-1R

BackgroundHair follicles play a crucial role in hair growth, wound healing, thermoregulation, and sebum production. Hair loss affects millions of people worldwide, yet therapeutic options for managing hair loss and pattern baldness are limited. Isoquercitrin (IQ), a natural small molecule from drinkable Chinese tea, is famous for anti-aging properties. PurposeThis study aimed to explore the potential of IQ in treating and preventing hair loss, along with its underlying mechanisms. MethodsThe adult male and female, as well as middle-aged female sprague dawley (SD) rats were used to conduct hair growth experiments in vivo. Signaling pathways and target protein identification were analyzed through western blotting, drug affinity responsive target stability (DARTS), cellular thermal shift assay (CETSA) and surface plasmon resonance (SPR) analyses. Further, the targets were confirmed through in vivo inhibition experiments. ResultsIQ is reported here to stimulate anagen phase initiation and hair regrowth by directly interacting with adenosine 5′-monophosphate-activated protein kinase (AMPK) and insulin-like growth factor 1 receptor (IGF-1R). This process involves the AMPK/mammalian target of rapamycin (mTOR)/ unc-51-like autophagy-activating kinase 1 (ULK1) signalling pathway to trigger autophagy and the IGF-1R/phosphatidylinositol 3-kinase (PI3 K)/protein Kinase B (AKT), vascular endothelial growth factor (VEGF)/ vascular endothelial growth factor receptor (VEGFR)/ angiotensin (ANG) pathways to promote angiogenesis in female rats. Furthermore, the hair regrowth efficacy of IQ in adult male rats and middle-aged female rats was verified and shown. Similarly, our findings indicate that IQ promotes hair regrowth in middle-aged rats through autophagy and angiogenesis, akin to its effects in adult rats. ConclusionAMPK and IGF-1R proteins are identified as the target proteins of IQ and the AMPK/mTOR/ULK1, IGF-1R/PI3K/AKT and VEGF/VEGFR/ANG signalling pathways take important roles in hair growth effect of IQ. Thus, these signaling pathways are crucial for developing future treatments and clinical strategies for hair regeneration.

Gender differences in adverse effects and dosing practices of low-dose oral minoxidil for androgenetic alopecia: a retrospective analysis of 310 patients

Introduction Off-label low-dose oral minoxidil (LDOM) is used for androgenetic alopecia (AGA) treatment, with limited safety data. We investigated LDOM adverse events (AEs) in AGA patients. Methods AGA patients taking LDOM were identified (1/1/2010–12/3/2022). AEs and management were recorded from follow-up and emergency room visits. Fisher’s exact test, logistic regression, and Benjamini-Hochberg Procedure assessed significance and adjusted for multiple comparisons. Results Three-hundred-ten AGA patients were analyzed with mean age 47.5 years and 53.2% females. Average LDOM dose was lower for females vs. males. AEs were observed in 14.9% of patients, with dizziness/lightheadedness, hypertrichosis, and extremity edema being most common. Higher doses were associated with increased likelihood of dizziness/lightheadedness. Females had higher overall incidence of AES; however, gender differences did not persist after subgroup analysis. Among patients experiencing AEs, 11.1% adjusted their dosage and 28.9% discontinued treatment. Conclusion Higher LDOM dose increased risk of dizziness/lightheadedness in both genders, with females more likely to experience any AE. Patients are often started at inappropriately high doses, causing AE induced regimen changes. Therefore, we recommend a cautious approach when prescribing LDOM, starting with lower doses and gradually increasing as tolerated, and counseling female patients regarding their higher risk of AEs.

Applications and efficacy of minoxidil in dermatology.

Minoxidil, originally developed as an antihypertensive medication, has evolved into a versatile therapeutic agent within dermatology, notably for its effectiveness in promoting hair growth. Despite its widespread use, understanding its precise mechanism of action remains a challenge. This paper addresses this gap by providing a comprehensive review of pharmacological properties, action mechanisms, clinical effectiveness and side effects associated with topical minoxidil. Furthermore, it highlights emerging trends and applications, including its role in treating androgenetic alopecia, its potential for alopecia areata management and its utilization in combination therapies. Additionally, this paper explores novel applications in scar treatment and wound healing. By synthesizing current knowledge and insights, this review adds clarity to the diverse applications of minoxidil, providing valuable guidance for clinicians and researchers aiming to optimize its therapeutic use in dermatology.

Investigation the role of SIRT3, SIRT7, NFATC1, and PDL-1 genes in androgenetic alopecia

BackgroundAndrogenetic alopecia (AGA) stands as the most prevalent form of hair loss, affecting the hair follicles (HFs). Aging emerges as a prominent contributor in this condition. In this study, our aim is to elucidate the expression patterns of candidate genes—SIRT3, SIRT7, NFATC1, and PDL-1—known to exhibit differential expression levels during HF aging, and to underscore the role of aging in AGA.Material and methodsMesenchymal stem cells (MSCs) were isolated from the vertex and occipital regions of six men affected by AGA. The aim was to assess the expression levels of SIRT3, SIRT7, NFATC1, and PDL-1 genes. RNA extraction was performed followed by cDNA synthesis, and gene expression levels were quantified using real-time PCR. To validate the experimental findings, two different RNA-seq datasets relevant to the study were analyzed using R software.ResultsIn the present study, experimental tests revealed that the expression levels of SIRT3 and SIRT7, known to decrease during HF aging, were diminished in AGA-affected samples as well. Conversely, the mean value of NFATC1 and PDL-1 expression level, which are known to increase during HF aging, were found to be elevated in AGA-affected samples. Moreover, bioinformatic analyses provide additional support for the role of SIRT3, SIRT7 and NFATC1in AGA pathogenesis.ConclusionWhile SIRT3 and SIRT7 may play critical roles in AGA development, further research is needed to elucidate the significance of NFATC1 and PDL-1 in this context and to explore their potential as therapeutic targets for AGA treatment.

Czy lek na jaskrę zrewolucjonizuje leczenie łysienia androgenowego? O repozycjonowaniu leku, którego efekt uboczny stał się pożądanym skutkiem terapii.

Prostaglandins are hormones found in almost all mammalian tissues. As signaling molecules, they play a key role in the regulation of many physiological processes, including hair growth cycle. The article describes the history of the discovery of prostaglandins, including the work of Professor Ryszard Gryglewski - the discoverer of prostacyclin. Particular attention was paid to the synthetic analogue of prostaglandin F2α - latanoprost. Indicated for the treatment of glaucoma, the drug is known for inducing eyelash growth as a side effect. A prodrug, latanoprost is converted to its active metabolite, latanoprost acid. Recent research demonstrated that latanoprost acid has a chance to become an effective alternative to minoxidil and finasteride - the only drugs currently registered for the treatment of androgenetic alopecia. The development of anti-alopecia drugs containing prostaglandin derivatives, including latanoprost acid, will be a much faster process compared to the traditional path of product development based on a new chemical compound.

Restoration of follicular β-catenin signaling by mesenchymal stem cells promotes hair growth in mice with androgenetic alopecia

BackgroundThe use of mesenchymal stem cells (MSCs) is recognized as a promising strategy for the treatment of androgenetic alopecia (AGA). However, the underlying mechanism remains to be explored. Here, we evaluated the therapeutic effects and potential mechanisms of the use of human umbilical cord mesenchymal stem cells (hUCMSCs) in dihydrotestosterone (DHT)-induced AGA models in vivo and in vitro.MethodsIntradermal transplantation of hUCMSCs was performed in AGA model mice and therapeutic effects were evaluated using histological and immunofluorescence staining. Transwell assays were used for co-culture of hUCMSCs and dermal papilla cells (DPCs), and communication was assessed using RT-qPCR, immunofluorescence, and apoptosis analysis. Interactions between DPCs and hair follicle stem cells (HFSCs) were investigated using RT-qPCR, EdU assays, and cell cycle analysis. ResultsTreatment of AGA mice with hUCMSCs promoted hair growth, HFs density, skin thickness, and anagen phase activation, while inhibiting DPCs apoptosis, and promoting HFSCs proliferation. In vitro, hUCMSCs activated Wnt/β-catenin signaling in DPCs via Wntless (Wls), while stimulating growth factor secretion and HFSCs proliferation. Blocking β-catenin degradation with MSAB increased DPCs apoptosis, reduced growth factor secretion, and retarded HFSCs proliferation.ConclusionhUCMSCs promoted hair regeneration in AGA model mice. This was found to be dependent on reducing DPCs apoptosis, thereby relieving the inhibitory effects of DPCs on the growth of HFSCs. The activation of the Wnt/β-catenin signaling pathway was shown to play a crucial role in the promotion of hair growth by hUCMSCs in AGA mice.

Efficacy of Ritlecitinib in Patients with Alopecia Areata by Extent of Hair Loss: Results from the Phase 2b/3 and Phase 3 ALLEGRO Clinical Trials

Introduction: Ritlecitinib, a dual JAK3/TEC family kinase inhibitor, demonstrated efficacy and safety in patients ≥12 years old with AA and ≥50% scalp hair loss in the phase 2b/3 ALLEGRO study. This post hoc, pooled analysis of the ALLEGRO-2b/3 and phase 3 ALLEGRO-LT studies evaluated the efficacy of ritlecitinib in patients with alopecia areata (AA) by extent of baseline scalp hair loss through Month 24. Methods: Patients aged ≥12 years with AA and ≥50% scalp hair loss who received ritlecitinib 50 mg daily in ALLEGRO-2b/3 and rolled over to ALLEGRO-LT (continued to receive 50 mg) were included. Outcomes included the proportions of patients achieving response based on Severity of Alopecia Tool [SALT] score ≤20 (≤20% scalp hair loss), ≥2-grade improvement in eyebrow assessment [EBA] score (among patients with abnormal score at baseline), and ≥2-grade improvement in eyelash assessment [ELA] score (among patients with abnormal score at baseline). Patients were stratified by extent of scalp hair loss at baseline, defined as severe AA (SALT score 50-94) or very severe AA (SALT score 95-100), as per the Alopecia Areata Investigator Global Assessment (AA-IGA). Data as observed and imputed (last observation carried forward [LOCF]) are reported at the cutoff date (December 9, 2022). Results: Of 191 patients included, 66 (34.6%) had severe AA and 125 (65.4%) had very severe AA at baseline. At Month 12, 64.4% and 34.3% (observed) and 60.6% and 29.6% (LOCF) of patients with severe AA and very severe AA, respectively, achieved SALT ≤20. At Month 24, these proportions increased to 70.2% and 54.8% (observed) and 63.6% and 36.8% (LOCF), respectively. EBA response was achieved in 54.6% and 46.9% (observed) and 52.8% and 42.4% (LOCF) of patients with severe AA and very severe AA, respectively, at Month 12; at Month 24, the proportions were 60.9% and 56.5% (observed) and 50.0% and 45.8% (LOCF). ELA response was achieved in 60.7% and 40.5% (observed) and 61.3% and 38.0% (LOCF) of patients with severe AA and very severe AA, respectively, at Month 12; at Month 24, the proportions were 70.0% and 45.3% (observed) and 61.3% and 38.0% (LOCF). Conclusion: Ritlecitinib 50 mg daily achieves scalp, eyebrow, and eyelash hair regrowth in patients with severe and very severe AA. Funding: This study was funded by Pfizer Inc

A Novel Nutraceutical Gummy for Hair Regrowth in Women: A Case Series

Introduction:Hair loss is a common concern among women, with female pattern hair loss (FPHL) and telogen effluvium (TE) being the most prevalent types. At least 50% of women experience hair loss by age 50 [1]. Many patients turn to nutritional supplements, with one hair loss clinic reporting that up to 81% of their patients use supplements [2]. While various nutraceuticals have demonstrated clinical efficacy in hair regrowth [2], none have been evaluated in gummy form. This case series aims to assess the efficacy of a novel nutraceutical gummy containing a proprietary blend of NAD, pumpkin seed extract, taurine, pea protein, ashwagandha, saw palmetto, and other anti-inflammatory ingredients in promoting hair regrowth in women with FPHL and TE. Procedure:Three women, aged 43, 52,64, with diagnoses of FPHL and TE, were included in this series. Each participant consumed two nutraceutical gummies daily for 2 or 3 months. One participant experiencing TE, also took oral minoxidil 1.25 mg daily. Baseline assessments included patient-reported outcomes related to hair shedding and photographic comparisons. Follow-up assessments were performed at 2 or 3 months. Results:All three women demonstrated noticeable improvements in hair density and a reduction in hair shedding by the 3-month mark. Participants also reported subjective improvements in hair quality, volume, and overall satisfaction with the product. No adverse effects were observed during the study period. Conclusion:This case series suggests that the novel nutraceutical gummy may be an effective, well-tolerated option for promoting hair regrowth in women with FPHL and TE. This nutraceutical can be efficacious as a sole treatment and in conjunction with traditional hair loss medical therapy. These findings highlight the potential for a gummy formulation to provide an accessible, evidence-based treatment for hair loss. Further studies with larger sample sizes are ongoing to validate these results.

A Prospective and Comparative Study to Explore the Effects of Platelet-Rich Plasma in Hair Transplantation for Patients With Androgenetic Alopecia.

Androgenetic alopecia (AGA) is the most prevalent type of hair loss. Traditionally, treatment for AGA has primarily involved the topical application of minoxidil in conjunction with oral finasteride or spironolactone. Recently, platelet-rich plasma (PRP) has emerged as a significant focus of research in hair loss treatment. However, many studies on PRP-assisted hair transplantation have encountered various limitations. This study aims to conduct a prospective, comparative clinical investigation to evaluate the therapeutic effects of combining PRP with minoxidil and finasteride/spironolactone as adjuncts to hair transplantation. From August 2019 to December 2022, we enrolled 30 patients with AGA in the study, randomly assigning them to an experimental group and a control group. The experimental group received drug therapy alongside hair transplantation and underwent PRP injections, whereas the control group received only drug therapy to assist with hair transplantation. Prior to surgery, no significant differences in baseline data were observed between the two groups. Following treatment, the experimental group demonstrated significantly improved follicle survival rates, follicle growth rates, and hair strength compared with the control group. This prospective, comparative clinical study demonstrated that the application of PRP in conjunction with pharmacological support during FUE treatment for AGA resulted in improved follicle survival rates, hair growth rates, and hair strength.

An Integrated Approach to Develop Innovative, Sustainable, and Effective Cosmetic Ingredients: The Case Report of Fatty-Acids-Enriched Wild Strawberry Waste Extract

The sourcing of raw materials with low environmental impact, e.g., “upcycled” ingredients from short supply chains, has currently become necessary, and agri-food waste represents a very attractive hub to produce innovative cosmetic extracts. In this paper, an integrated approach considering all the different steps, starting from material selection, extraction, chemical characterization, biological activity evaluation, and environmental impact calculation, was adopted to obtain innovative, sustainable, and effective cosmetic raw materials from food waste. As case report, a supercritical CO2 extract obtained from wild-strawberry-processing waste after jam production (WSWSCO2 extract) was developed. The fatty acids profile of the waste material and WSWSCO2 extract was investigated via a GC–MS method, and mainly polyunsaturated fatty acids (PUFAs) such as linoleic and linolenic acids were detected. Furthermore, the ability of the WSWSCO2 extract to inhibit 5α-reductase type 1 expression in skin fibroblasts was assessed, confirming significant efficacy at the dose of 5 mg/mL. Finally, in view of the eco-sustainability approach, the environmental impact related to WSWSCO2 extract was calculated using a life cycle assessment (LCA) analytical approach, considering different parameters and indicators (e.g., carbon footprint) and verifying the eco-friendly approach in extract development and production. Although further research is needed, for example, to check the full composition of the extract and its effect on skin cells, these results suggest that the WSWSCO2 extract may represent an innovative and sustainable ingredient for cosmetic applications especially in topical preparation for the treatment of some androgenic-related discomfort, such as acne and androgenic alopecia, reflecting the potentiality of the holistic and pioneering approach related to ingredient development presented in this study for the cosmetic sector.

The reasons and solutions for lipsotrichia and pelada phenomenon

Abstract. According to Darwins evolution, people know that humans evolved from certain types of apes which used to have a lot of hair. In the process of evolving from apes to humans, apes hair was lost gradually. Nowadays, there is only a little bit of hair that modern humans still left, like hair on the heads and four limbs. NLM database reported an experiment that justified hair on the heads can protect human brains by reducing solar radiation. But many people, because of some reasons, like genes, immune system, and endocrine, have hair loss problems, which leads to possible damage to their brain and appearance. This paper aims to explore the way to mitigate scarring alopecia and androgenetic alopecia. The results show that people can prevent their hair by changing their life habits cleaning their scalps carefully and having a good mood. If they already get scarring alopecia, people must take medicine based on medical advice. And if people get androgenetic alopecia, they should use Minoxidil. This paper can help people with hair loss problems grow their hair back so that it can better help the brain dissipate heat.

Skin as a mirror of metabolic syndrome: Do some dermatoses alarm internal metabolic sinister?

Metabolic syndrome is a group of abnormalities in metabolism including hypertension, central obesity, insulin resistance and dyslipidaemia. Etiopathogenesis is multifactorial including genetic and environmental factors. It is more prevalent in recent decade due to sedentary lifestyle with unhygienic food habits and cause increased prevalence in younger age group. This abnormal metabolism leads to oxidative stress in body involving multiple inflammatory pathways. There are so many dermatoses which are associated with metabolic syndrome due to common factors are involved in etiopathogenesis. These includes psoriasis, acne vulgaris, acanthosis nigricans, hidradenitis suppurativa, atopic dermatitis, androgenetic alopecia, lichen planus. There is increased risk of developing diabetes mellitus and damage to cardiovascular system. Early diagnosis and management are required to reduce risk of complications. These includes active lifestyle, dietary changes and medications.